With a $53.4 million market capitalization, NovaBay Pharmaceuticals (NBY) has given long-term shareholders a volatile year with a 52-week share range of $1.05-$1.76. For much of 2013, the company's common shares have traded around the $1.25 support/resistance range, just below the $1.40 resistance level it currently resides at. If there were no significant catalysts for 2H 2013, the company's shares could be in danger of returning closer to the mid-term $1.0 support range. However, significant events from its developing pipeline as well as potential upcoming updates of its single product offering may present investors with significant volatility in the coming weeks with much upside possible if events unfold favorably.
On June 11, NovaBay presented investors with a ...
Only subscribers can access this article, which is part of the PRO research library covering 3,611 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: